Intercept Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Intercept Pharmaceuticals

02/03/2023 14:36

* Intercept Pharmaceuticals Inc  ICPT.OQ  reported a
quarterly
adjusted loss of 50 cents​​ per share for the quarter ended in
December. The mean expectation of sixteen analysts for the
quarter was for a loss of 16 cents per share.
    * Revenue fell 16.4% to $77.22 million from a year ago;
analysts
expected $78.08 million. 
    * Intercept Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 50 cents​.
    * The mean earnings estimate of analysts had risen by
about 59.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Intercept Pharmaceuticals Inc shares had risen by 60.1%
this
quarter.
    * The company reported a quarterly loss of $20.82 million.
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $21.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 2
at 02:36 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.16          -0.50          Missed
 Sep. 30 2022      4.61           7.80           Beat
 Jun. 30 2022      -0.49          -0.68          Missed
 Mar. 31 2022      -0.90          -0.58          Beat